Login / Signup

Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder.

Sophie KöhneThomas HillemacherAlexander GlahnPatrick Bach
Published in: Expert opinion on emerging drugs (2024)
Even though the majority of the discussed compounds lack sufficient evidence to support their efficacy, multiple promising new treatment options are currently under investigation. Future research has to consider specific phenotypes and subgroups of AUD as well as a possible enhancement of the effects of psychotherapy through combination with pharmacotherapy. Practitioners should be encouraged to use available compounds to support existing therapeutic regimens.
Keyphrases
  • alcohol use disorder
  • phase ii
  • clinical trial
  • open label
  • primary care
  • smoking cessation
  • current status
  • double blind
  • randomized controlled trial
  • placebo controlled
  • replacement therapy